



Zacharon Pharmaceuticals Enters Into Agreement with Acorda Therapeutics to Develop Small Molecules Targeting Spinal Cord Injury

Collaboration to Selectively Target Chondroitin Sulfate Biosynthesis

SAN DIEGO, April 30, 2012 – Zacharon Pharmaceuticals has entered into a research agreement with Acorda Therapeutics to develop small molecule chondroitin sulfate modulators as potential therapeutics for treatment of spinal cord injury. Such small molecule modulators that cross the blood-brain barrier could promote neuronal regeneration following injury. The agreement includes research funding with an option for further development; financial terms were not disclosed.

Chondroitin sulfate proteoglycans that are made following a spinal cord injury are known to specifically inhibit neuronal regeneration. Zacharon Pharmaceuticals has discovered small molecule modulators of chondroitin sulfate using its proprietary glycan modulator discovery platform consisting of Sensi-Pro[®] technology with cellular assay systems to assess structural modulation of glycans.

“We are excited to be working with Acorda, who are leaders in developing potential spinal cord injury treatments,” stated Robin Jackman, Ph.D., president and CEO of Zacharon. “We look forward to combining their expertise in spinal cord injury research with our first-in-class small molecule glycan modulators.”

About Zacharon Pharmaceuticals, Inc.

Zacharon Pharmaceuticals, Inc. is a biotechnology company leveraging unique glycobiology expertise to develop a new class of human therapeutics targeting the biosynthesis of glycans. Glycans encompass an attractive selection of specific and potent drug targets for a variety of diseases. Zacharon has created breakthrough assay technologies integrating cell-based

screening with highly sensitive glycan structural analysis tools, providing a unique and powerful platform for novel small molecule drug discovery. Zacharon's most advanced drug development programs target several forms of lysosomal storage disease and several rare forms of cancer. Additional applications exist across a wide range of therapeutic classes. The glycan-targeted assay technologies developed by Zacharon are also being applied beyond the company's drug development programs towards clinical biomarkers and diagnostics for glycan-related diseases.

For more information, please visit www.zacharon.com.